Skip to main content
. 2019 Jul 4;105(3):820–828. doi: 10.3324/haematol.2019.223966

Figure 2.

Figure 2

Effects of treatments in part 1 and part 2 of the study in the four individuals who received long-term eltrombopag therapy. The figure summarizes the effects of eltrombopag administration on bleeding symptoms according to the World Health Organization (WHO) bleeding scale and on platelet count. Patients 1/1 and 12/10 have MYH9-related disease, patient 17/13 has ITGB3-RT, and patient 22/16 has Wiskott-Aldrich syndrome (see Table 5).